AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study
ONL closed the second tranche of a $46.9 million Series B financing round earlier this year ONL now preparing IND filing for a Phase 2 study of ONL1204 Ophthalmic Solution AmbioPharm providing manufacturing support for ONL1204 NORTH AUGUSTA, S.C. & ANN ARBOR, Mich.–(BUSINESS WIRE)–#CPHI–AmbioPharm, a global peptide CDMO, is a key partner in peptide manufacturing … [Read more…]
